Reuter H D, Thiele S, Hönig R
Medizinischen Universitätsklinik I, Köln-Lindenthal.
Arzneimittelforschung. 1988 May;38(5):727-9.
In recent investigations it was found that ciprofloxacin (1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7 (1-piperazinyl)-3-fiquinoline-carboxylic acid, Ciprobay) in concentrations similar to maximal levels obtained in the serum of patients with normal renal function after application of therapeutic doses and 4- to 5fold such concentrations does not influence aggregation induced by epinephrine and collagen in platelet rich plasma of healthy subjects. Because in literature there are several reports about disturbances of platelet aggregation in patients with renal failure treated with antibiotics and because renal failure often is accompanied by defect platelet function the effect of ciprofloxacin on epinephrine and collagen induced aggregation was studied in platelet rich plasma of patients with chronic renal failure undergoing dialysis. Compared to platelets from patients with renal failure which had been incubated with saline instead of ciprofloxacin, patients platelets under the influence of ciprofloxacin did not show any significant differences. From this we conclude that the defect which may be present in platelets of patients with chronic renal failure is not further increased by ciprofloxacin.
在最近的研究中发现，环丙沙星（1-环丙基-6-氟-1,4-二氢-4-氧代-7-(1-哌嗪基)-3-喹啉羧酸，拜复乐）在浓度与治疗剂量应用后肾功能正常患者血清中获得的最大水平相似以及该浓度的4至5倍时，并不影响健康受试者富血小板血浆中肾上腺素和胶原诱导的聚集。由于文献中有几篇关于用抗生素治疗的肾衰竭患者血小板聚集紊乱的报道，并且由于肾衰竭常伴有血小板功能缺陷，因此在接受透析的慢性肾衰竭患者的富血小板血浆中研究了环丙沙星对肾上腺素和胶原诱导聚集的影响。与用生理盐水而非环丙沙星孵育的肾衰竭患者的血小板相比，受环丙沙星影响的患者血小板没有显示出任何显著差异。由此我们得出结论，环丙沙星不会进一步加重慢性肾衰竭患者血小板中可能存在的缺陷。
